Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Bolsters Januvia Access With Outcomes-Based Discounts To CIGNA

Executive Summary

Merck will provide CIGNA with price discounts on Januvia and Janumet that are tied to member outcomes - lower blood sugar and medication adherence - in a novel contract arrangement announced by CIGNA April 23

You may also be interested in...



Payers’ Use Of Real-World Evidence For Drug Coverage On The Rise – IMS Health

A new study by IMS Health shows payers globally are making more drug reimbursement decisions based on real-world evidence – including 25% of more than 100 identified case studies using biopharma industry-generated data.

Express Scripts Dispute With Walgreens Spotlights PBMs’ Thirst For Deeper Discounts

The contracting dispute between the drug chain and PBM may also presage tougher negotiations ahead for biopharmaceutical companies, particularly if Express Scripts is successful in its bid to acquire rival PBM Medco.

J&J Pushes New Treatment Paradigm for Invega Sustenna

Johnson & Johnson is looking at innovative ways to build the value of its just-approved, monthly injectable schizophrenia drug Invega Sustenna, including continuing ongoing outcomes studies and creating appropriate partnerships with payers and others, as part of a broader plan for a "new treatment paradigm" in the treatment of schizophrenia

Related Content

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel